德谷胰岛素与甘精胰岛素U100治疗2型糖尿病高心血管风险患者的住院费用比较
本数据集基于DEVOTE试验的严重不良事件数据，比较了德谷胰岛素与甘精胰岛素U100在2型糖尿病高心血管风险患者中的加拿大住院费用，结果显示德谷胰岛素组平均年成本更低。
基本信息
资源简介
德谷胰岛素与甘精胰岛素U100治疗2型糖尿病高心血管风险患者的住院费用比较
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 2 个文件、合计 579.62 KB，主题涵盖 Health-economic analysis、basal insulin analogue、cardiovascular outcomes trial、serious adverse events、diabetes mellitus，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial》。配套论文《Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial》发表于 Journal of Medical Economics（2021），DOI：10.1080/13696998.2021.2003804。源站首次发布：2021-11-12。
【数据内容】
源站原始描述：The present cost–consequence analysis compared estimated hospitalization costs in a Canadian setting with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Medical terms were mapped across the different vocabularies, in order to assign unit costs from eligible hospital abstracts in Canadian Institute for Health Information data (International Statistical Classification of Diseases and Related…
【数据结构与技术规格】
文件数 2 个，合计 579.62 KB。ijme_a_2003804_sm2160.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，431.63 KB。ijme_a_2003804_sm2154.xlsx：application/vnd.openxmlformats-officedocument.spreadsheetml.sheet，147.98 KB。数据集 DOI：10.6084/m9.figshare.16995201.v1。
【主题与分类】
源站学科分类：Medicine、Sociology、Marine Biology、Science Policy。主题标签：Health-economic analysis、basal insulin analogue、cardiovascular outcomes trial、serious adverse events、diabetes mellitus、I1、I10、I13、I15。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Hospitalization_costs_with_degludec_versus_glargine_U100_for_patients_with_type_2_diabetes_at_high_cardiovascular_risk_Canadian_costs_applied_to_SAEs_from_a_randomized_outcomes_trial/16995201
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Taylor & Francis. Tarride, Jean-Eric; Husain, Mansoor; Andersen, Andreas; Gundgaard, Jens; Luckevich, Maria; Mark,…
【使用注意】
· 源站最后修改于 2023-06-04，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial
- DOI：10.6084/m9.figshare.16995201.v1
- 发布日期：2021-11-12
- 文件数：2 个
- 文件总体积：579.62 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Hospitalization_costs_with_degludec_versus_glargine_U100_for_patients_with_type_2_diabetes_at_high_cardiovascular_risk_Canadian_costs_applied_to_SAEs_from_a_randomized_outcomes_trial/16995201
命令行下载
curl -L -o "ijme_a_2003804_sm2160.docx" "https://ndownloader.figshare.com/files/31438545"
curl -L -o "ijme_a_2003804_sm2154.xlsx" "https://ndownloader.figshare.com/files/31438548"
文件清单
ijme_a_2003804_sm2160.docx（431.63 KB）ijme_a_2003804_sm2154.xlsx（147.98 KB）
文件总体积 579.62 KB（源站 API 实测）。
数据说明
The present cost–consequence analysis compared estimated hospitalization costs in a Canadian setting with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk.
Medical terms were mapped across the different vocabularies, in order to assign unit costs from eligible hospital abstracts in Canadian Institute for Health Information data (International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Canada) to serious adverse events (SAEs; Medical Dictionary for Regulatory Activities) from the randomized DEVOTE trial comparing the two insulins degludec and glargine. Mean annual costs of SAE-related hospitalizations were estimated by treatment, the cost difference (degludec − glargine U100) was bootstrapped to compute confidence intervals (CIs) and p-values, and the cost ratio (degludec/glargine U100) was estimated using a Tweedie distribution.
The mean annual cost per patient for SAE-related hospitalizations was 4,074 CAD with degludec and 4,569 CAD with glargine U100 (cost difference: −495, 95% confidence interval [CI]: −966; −24, p = .039), for a cost ratio of 0.89 (95% CI: 0.81; 0.98, p = .016). Overall, cost ratios from sensitivity analyses varying individual methodological assumptions were consistent with the main analysis. Of the system organ classes from DEVOTE SAEs, cardiac disorders were the largest contributor to the costs savings with degludec versus glargine U100.
In patients with T2D at high CV risk, our findings suggest that there are likely to be lower hospitalization costs with degludec versus glargine U100 based on the SAEs observed in DEVOTE and in a Canadian setting.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.16995201.v1（source: https://tandf.figshare.com/articles/dataset/Hospitalization_costs_with_degludec_versus_glargine_U100_for_patients_with_type_2_diabetes_at_high_cardiovascular_risk_Canadian_costs_applied_to_SAEs_from_a_randomized_outcomes_trial/16995201）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
